WallStreetZenWallStreetZen

NASDAQ: TELO
Telomir Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TELO stock forecasts and price targets.

Forecast return on equity

Is TELO forecast to generate an efficient return?

Company
-1,666.24%
Industry
1,293.18%
Market
72.13%
TELO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TELO forecast to generate an efficient return on assets?

Company
-809.25%
Industry
932.61%
TELO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TELO earnings per share forecast

What is TELO's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.40
Avg 2 year Forecast
-$0.36

TELO revenue forecast

What is TELO's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$1.5M

TELO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TELO$2.55N/AN/A
IVVD$0.63$7.52+1,093.17%Strong Buy
SAVA$1.56$2.00+28.21%Hold
IMAB$0.94$5.50+485.11%Buy
NTRB$6.88$13.00+88.95%Buy
View Top Biotech Stocks

Telomir Pharmaceuticals Stock Forecast FAQ

What is TELO's earnings growth forecast for 2025-2026?

(NASDAQ: TELO) Telomir Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 31.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 65.68%.

Telomir Pharmaceuticals's earnings in 2025 is -$16,532,716.On average, 1 Wall Street analyst forecast TELO's earnings for 2025 to be -$11,905,068, with the lowest TELO earnings forecast at -$11,905,068, and the highest TELO earnings forecast at -$11,905,068.

In 2026, TELO is forecast to generate -$10,714,562 in earnings, with the lowest earnings forecast at -$10,714,562 and the highest earnings forecast at -$10,714,562.

If you're new to stock investing, here's how to buy Telomir Pharmaceuticals stock.

What is TELO's revenue growth forecast for 2026-2026?

(NASDAQ: TELO) Telomir Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 3,212.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.69%.

Telomir Pharmaceuticals's revenue in 2025 is $0.

In 2026, TELO is forecast to generate $44,644,007 in revenue, with the lowest revenue forecast at $44,644,007 and the highest revenue forecast at $44,644,007.

What is TELO's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: TELO) forecast ROA is -809.25%, which is lower than the forecast US Biotechnology industry average of 932.61%.

What is TELO's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: TELO) Telomir Pharmaceuticals's current Earnings Per Share (EPS) is -$0.56. On average, analysts forecast that TELO's EPS will be -$0.40 for 2025, with the lowest EPS forecast at -$0.40, and the highest EPS forecast at -$0.40. In 2026, TELO's EPS is forecast to hit -$0.36 (min: -$0.36, max: -$0.36).

What is TELO's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: TELO) forecast ROE is -1,666.24%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.